Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
- Saturday, May 1, 2021, 7:00
- Finance
- Add a comment
EAST HANOVER, N.J., May 1, 2021 /PRNewswire/ — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of BEOVU® (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of…
About the Author
adminasapcorp has written 41268 stories on this site.